AGTC Sheds Light On Achromatopsia Trials, Eli Lilly, VIR And GSK Team Up, CVM Turns Head As It Awaits Data
(3) LONDON (dpa-AFX) - Today's Daily Dose brings you news about Applied Genetic's Achromatopsia trial results; the deadlock in AstraZeneca vaccine supply in EU; partnership of Lilly, Vir Biotech and GlaxoSmithKline in fighting COVID-19; and ZymeWork's progress with ZW49 study. Read on. 1. Applied Genetic Throws Light on Achromatopsia Trials Applied Genetic Technologies Corp.'s (AGTC) phase I/II clinical trials evaluating AAV gene therapy product candidates in patients with achromatopsia caused by CNGB3 or CNGA3 mutations, dubbed ACHMB3 and ACHMA3 trials, have provided for the first time quan...
Source: finanznachrichten.de